A little help with the numbers
Useful calculators
Choose a calculator. It opens just below.
Have your reports to hand, and ask your care team about anything you are unsure of.
Review information is shown with each calculator.
Medical disclaimer · applies to all calculators
All calculators on this page are for educational purposes only. They help patients and caregivers understand measurements, clinical scores and risk estimates, but cannot predict an individual’s outcome or replace medical advice. Do not use a result to make treatment or follow-up decisions. Please discuss it with your treating doctor or oncologist, who can confirm the information entered and interpret the result alongside your reports and overall health.
Your privacy: Your answers stay in this browser tab. They are not sent to a server or saved by these calculators. Switching calculators keeps your answers in the open page. Use Clear answers to reset a form; reloading or closing the page clears all answers.
Select a calculator above to get started.
Body surface area
Body surface area (BSA) estimates the area of your skin in square metres (m²), using your height and weight. Your care team may use it when planning treatment.
What you’ll need
- Your current measured height and weight.
- The units for each measurement, such as cm and kg.
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
Carboplatin dose
For use with the oncology team. Choose a known GFR (a measure of kidney filtering) or estimate it here from creatinine, age, sex, height and weight. Then enter the prescribed target AUC, which describes the intended drug exposure, to calculate the formula dose.
What you’ll need
- The target AUC prescribed by your oncology team.
- Either a known GFR and its exact units, or serum creatinine with its units, age, sex, height and actual weight.
- Height and weight are also needed if a known GFR is indexed to 1.73 m².
- Your team’s confirmation that the selected kidney assessment and equation suit the treatment protocol.
Specified update approved by Dr (Prof) Vijay AgarwalReview record updated: AUC units in the prescribed target label and its matching help only; calculation and prescribing choices unchanged. This approval covers the specified update; it is not a new whole-tool review.
Estimated kidney function
Estimated glomerular filtration rate (eGFR) estimates how well your kidneys filter blood. This tool uses your age, blood creatinine level and the sex parameter in the equation. Creatinine is a waste product made mainly by muscles and removed by the kidneys. Ask your care team whether this estimate is suitable for you.
What you’ll need
- Your age in completed years.
- Your blood creatinine result (called serum creatinine on the report) and the units shown beside it. The default unit here is mg/dL.
- Your care team’s confirmation that kidney function is stable and that this equation is suitable.
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
Corrected calcium
Some calcium in the blood is attached to albumin, a blood protein. This tool uses your total calcium and albumin results to calculate an adjusted calcium estimate. Your care team can explain whether this estimate is useful for you.
What you’ll need
- Total calcium and albumin results from the same blood sample or clinical assessment, as advised by your care team.
- The units beside both values on your report. The defaults here are mg/dL for calcium and g/dL for albumin.
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
Performance status
Performance status describes how illness affects everyday life. This form records an Eastern Cooperative Oncology Group (ECOG) grade and a Karnofsky performance status (KPS) score using separate descriptions agreed with your care team.
What you’ll need
- An assessment of usual daily activity, self-care and time spent in bed or a chair.
- Your clinician’s assessment of the help and medical care needed. If Karnofsky is not known, choose “Not assessed”.
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
Liver assessment
The Child–Pugh score helps assess cirrhosis, a condition involving scarring of the liver. It uses three blood results and two findings assessed by your clinician.
What you’ll need
- Total bilirubin, albumin and INR (a blood-clotting test), with the reported units.
- Your clinician’s assessment of abdominal fluid (ascites) and liver-related brain-function changes (hepatic encephalopathy).
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
ALBI score
The albumin–bilirubin (ALBI) score uses two blood results to help describe liver function in hepatocellular carcinoma (HCC), the most common type of primary liver cancer.
What you’ll need
- Serum albumin and total bilirubin from the same blood test or clinical assessment.
- The units printed beside each result.
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
Kidney cancer risk group
The International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score uses six factors to classify risk in kidney cancer that has spread to distant parts of the body. It is used with a clinical assessment when planning systemic therapy — medicines that act throughout the body.
What you’ll need
- A Karnofsky performance score assessed by your clinician. This describes your ability to carry out everyday activities. Open the performance status calculator.
- The time from the initial kidney cancer diagnosis to the first systemic treatment for metastatic disease (cancer that has spread).
- Blood results from before the treatment being assessed: haemoglobin, corrected calcium, absolute neutrophil count and platelet count, with the laboratory’s normal ranges.
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
GIST recurrence risk
A gastrointestinal stromal tumour (GIST) starts in the wall of the digestive tract. Recurrence means the tumour returning after treatment. Use your final surgical pathology report (the laboratory report on the tumour removed during surgery) and discuss the result with your treating team. Read the GIST guide
What you’ll need
- Your final surgical pathology report, including tumour site, size and mitotic count with its units.
- Confirmation about surgery, tumour rupture, subtype and any targeted therapy.
Understand the risk of GIST returning after surgery
Answer the eight questions below, then choose a method to see its risk assessment. Modified NIH (Joensuu) is selected to start. You can switch to AFIP (Miettinen–Lasota) using the same answers.
Medically reviewed and approved by Dr (Prof) Vijay AgarwalProfessor and Lead Consultant – Medical OncologyReview record updated:
The interactive calculator requires JavaScript. If it is unavailable, ask your treating team to explain the recurrence risk shown by your pathology findings.
About this result and its sources
Modified NIH (Joensuu)
The modified National Institutes of Health (NIH), or Joensuu, classification uses tumour size, mitotic count, starting site and rupture. It assigns a recurrence risk category: very low, low, intermediate or high. It does not provide an exact percentage or a fixed time period. Rupture places a tumour in the high-risk category.
AFIP (Miettinen–Lasota)
The Armed Forces Institute of Pathology (AFIP), or Miettinen–Lasota, classification uses tumour size, mitotic count and the specific starting site. Its percentages describe progressive disease: spread to another part of the body or death caused by GIST during long-term follow-up in groups studied before imatinib was available. They are not fixed five-year recurrence estimates or predictions of your individual outcome.
AFIP does not include tumour rupture. This calculator therefore withholds its result when rupture is reported. It provides direct site-specific results for the stomach, duodenum, jejunum or ileum, and rectum. It does not substitute another site when a site or table entry is unavailable, and it explains when the published evidence is too limited for a percentage.
The lookup uses the September 2026 College of American Pathologists (CAP) table. Published versions can differ: for a stomach tumour larger than 10 cm with 5 or fewer mitoses per 5 mm², this version gives 12%; the GEIS 2023 table gives 10%.
The two methods group findings differently and can give different categories. An AFIP percentage is not a conversion of a modified NIH category.
The surgery, treatment, subtype and reporting-unit questions check whether this calculator can be used. They do not add points to either classification. This calculator does not provide results for certain uncommon subtypes, uncertain information or situations outside its scope. The accepted input ranges are safeguards, not risk-category cut-offs.
Neither method estimates the benefit of imatinib or chooses a dose. Decisions about treatment after surgery also depend on whether the tumour’s gene changes make it sensitive to imatinib and on your clinical situation.
WE ARE HERE TO HELP
Let’s take the next step together.
Talk to our cancer care team about an appointment, a second opinion or choosing a centre.
Scan to WhatsApp